A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Abstract

Purpose According to the requirements of the “Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions”, this health technology assessment provides an evidence-based basis for drug selection and rational clinical use of glucagon-like peptide-1 receptor agonist drugs in medical institutions. Methods We consult the drug instructions, clinical treatment guidelines and search relevant documents in databases such as China national knowledge infrastructure, Wanfang, PubMed, and government websites such as National Medical Products Administration, Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency to collect and sort out the relevant information of the indications, pharmacological effects, guideline recommendations, drug prices and other information of glucagon-like peptide-1 receptor agonists, using a percentile system systematically evaluate the five dimensions of glucagon-like peptide-1 receptor agonists in terms of pharmaceutical properties, efficacy, safety, economy, and other attributes. Results The final scores of the evaluation results from high to low are semaglutide (71.00 points), dulaglutide (68.75 points), liraglutide (67.50 points), exenatide (67.00 points), lixisenatide (63.50 points), polyethylene glycol loxenatide (58.00 points) and benaglutide (49.00 points). Conclusion In clinical practice, semaglutide and dulaglutide are the top two drugs that can be used as recommended drugs. This health technology assessment can provide an evidence-based basis for hospital selection and rational use of glucagon-like peptide-1 receptor agonists. Clinicians can rationally choose and use drugs according to the patient’s conditions and needs.

Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

“…The current evaluation of the 7 GLP-1 RAs was based on the second version of the guideline, which is consistent with the previous evaluation of the first version, which recommended semaglutide (71.00 points), dulaglutide (68.75 points), and liraglutide (67.50 points) as the recommended drugs. 31 With further updates to the guidelines and support from other high-quality evidence-based medicine, the results of the two assessments are consistent, indicating that the results of this health technology assessment are reliable, and representative.…”

Transforming diabetes care: Latest advancements in treatment and technology

“…Based on their high scores of 71.5, 68.9, and 68.7, respectively, these three medications were recommended as the top choices for healthcare organisations looking to introduce GLP-1RAs. This comprehensive health technology assessment was conducted under the guidance of the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions [8] . The study evaluated the medications based on safety, efficacy, economy, and pharmacological qualities through a systematic assessment of sources such as PubMed, Cochrane, and Embase, in addition to drug labels and clinical guidelines.…”